Published in Archives

Consider it accepted — Weekly Glance

This is editorially independent content
1 min read

The FDA accepted Novaliq’s New Drug Application for its dry eye treatment, NOV03. If this sounds familiar, it should—I covered it in September. Below is a refresher.

What is NOV03?

NOV03 is a preservative-free, investigational eye drop designed to treat the signs and symptoms of dry eye disease associated with meibomian gland dysfunction.

It works by stabilizing the lipid layer to prevent aqueous evaporation and has the ability to penetrate the meibomian glands, where it has been reported to interact with and dissolve the altered viscous meibum in the glands.

When might we be able to prescribe this?

Maybe next year. The company has a Prescription Drug User Fee Act action date of June 28, 2023. (via)